Drug intelligence / Profile preview

STP206

Development stage: Phase 1
Lead developer: Sigma Tau Pharmaceuticals
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

STP206 is an investigational, orally administered live biotherapeutic product comprising *Lactobacillus acidophilus* and *Bifidobacterium animalis* subsp. *lactis*. It was developed by Sigma-Tau Pharmaceuticals, subsequently renamed Leadiant Biosciences, as a pharmaceutical-grade microbiome therapy intended to reduce the risk of necrotizing enterocolitis in very-low-birth-weight and extremely-low-birth-weight premature infants. The product received FDA orphan-drug designation for prevention of necrotizing enterocolitis and was evaluated in completed Phase 1 studies in healthy adults and premature neonates. ([firstwordpharma.com](https://firstwordpharma.com/story/2533395))

Beyond the preview

Go deeper on STP206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STP206.

Explore the full profile